ReviewHuman vaccines & immunotherapeutics2021
Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
Review in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients.Medicine · 2022Pooled it
- An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Pooled it
- Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) on the Efficacy of Immunotherapy in Metastatic NSCLC.Medical sciences (Basel, Switzerland) · 2026Observational
- Immunological Drug-Drug Interactions in Immune Checkpoint Inhibitor Therapy: Mechanisms, Clinical Evidence, and Artificial Intelligence.Current oncology reports · 2026Review
- Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors.International journal of molecular sciences · 2026Review
- Real-world management and outcomes of immune-mediated diarrhea and colitis: gaps in guideline adherence and opportunities for implementation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Perspective of smart nanocapsule swallowable laser-guided for integrated sensing and crispr-mediated cancer gene editing.Cancer gene therapy · 2026Review
- Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study.BMC cancer · 2026Article
- Effect of the Combination of Concomitant Drugs on Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Acetaminophen interactions with immune checkpoint inhibitors: guilt by association?Journal for immunotherapy of cancer · 2025Article
- Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?Biomedicines · 2025Review
- The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review.Oncology research · 2025Review
- Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis.Frontiers in immunology · 2025Article
- Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge.Biomedicines · 2024Article
- Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.Journal of cancer research and clinical oncology · 2024Article
- Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy.Cancer medicine · 2024Review
- Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response.Current oncology (Toronto, Ont.) · 2023Review
- Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.Current oncology (Toronto, Ont.) · 2023Article
- Impact of antibiotic use before definitive concurrent chemoradiation in patients with locally advanced non-small cell lung cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The majority of cancer patients assume concomitant medications for the treatment of cancer-related symptoms or co-morbidities. As immune checkpoint inhibitors expand in the treatment of a widening range of malignancies, drug-drug interactions have become an area of increasing interest due to the potential for some concomitant medications to exert immune-modulatory effects and influence outcomes from immunotherapy. Here, we review the evidence supporting this association across selected drug classes including antibiotics, proton pump inhibitors, metformin, and opioids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.